BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

364.65 +3.00 (+0.83%)

Delayed Quote Updated: 9:53 AM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BeOne Medicines Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 Next >

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

June 26, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®

June 25, 2025

From BeOne Medicines Ltd.

Via Business Wire

Earnings Preview: BeiGene ↗

May 13, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

AppLovin, First Solar And Li Auto Are Among Top 10 Large Cap Losers Last Week (June 16-20): Are The Others In Your Portfolio? ↗

June 22, 2025

Top 10 worst performing large-cap stocks last week: APP, FSLR, JHX, ONC, GSK, ACN, ANET, LI, CPAY, MA. Reasons include short-sell report, tax bill, and market selloff.

Via Benzinga

CureVac, TELUS International, Oracle And Other Big Stocks Moving Higher On Thursday ↗

June 12, 2025

Via Benzinga

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

June 12, 2025

From BeOne Medicines Ltd.

Via Business Wire

U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications

June 11, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025

June 11, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

June 02, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

May 31, 2025

From BeOne Medicines Ltd.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

May 27, 2025

Via Benzinga

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

May 27, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer

May 27, 2025

From BeiGene, Ltd.

Via Business Wire

BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors

May 22, 2025

From BeiGene, Ltd.

Via Business Wire

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗

May 21, 2025

Via The Motley Fool

Topics Economy Law Enforcement

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

May 14, 2025

From BeiGene, Ltd.

Via Business Wire

Earnings Scheduled For May 14, 2025 ↗

May 14, 2025

Via Benzinga

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

May 13, 2025

From BeiGene, Ltd.

Via Business Wire

Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat ↗

May 07, 2025

BeiGene posted a surprise Q1 profit and $1.12 billion in revenue, with strong U.S. Brukinsa sales, while reaffirming its 2025 outlook and margin guidance.

Via Benzinga

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

May 07, 2025

From BeiGene, Ltd.

Via Business Wire

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

April 29, 2025

From BeiGene, Ltd.

Via Business Wire

Benzinga Bulls And Bears: Netflix, Novavax, Intel — And The Market Begins To Bounce Back ↗

April 26, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial ↗

April 23, 2025

The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.

Via Stocktwits

Why Is Summit Therapeutics Stock Soaring On Wednesday? ↗

April 23, 2025

Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway.

Via Benzinga

BeiGene to Announce First Quarter 2025 Financial Results on May 7

April 17, 2025

From BeiGene, Ltd.

Via Business Wire

Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday ↗

April 11, 2025

Via Benzinga

Forecasting The Future: 4 Analyst Projections For BeiGene ↗

April 10, 2025

Via Benzinga

This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

April 07, 2025

Via Benzinga

BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit ↗

April 03, 2025

BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.